SkinHealth Systems Inc. SKIN NASDAQ · Healthcare · United States
$12.46 -10.23% -$1.42
Summary
36 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- Revenue fell by 6.3% a year over the last 3 years.
- Analysts expect revenue to fall by 5.2% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it fell by 6.3% a year. For the next fiscal year analysts expect revenue to fall by 5.2%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $18.3M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 14.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 4
- Hold 7
- Sell 3
Today's price within the analysts' price targets
The average target of $8.5 is 32% below today's price. 29% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Consumables 71%
- Delivery Systems 29%
By region
- Americas 68%
- EMEA 23%
- Asia Pacific 9.5%
Consumables brings in 71% of revenue.
Segments in detail